original articlessupportive careA randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
supportive care
Under a Creative Commons license
open access
Key words
neurokinin-1 receptor antagonist
NEPA
netupitant
palonosetron
CINV
moderately emetogenic
Cited by (0)
Copyright © 2014 THE AUTHORS. Published by Elsevier Ltd.